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Abstract
In a previous issue of the journal, Oldřich Coufal and Vuk Fait reported a pilot study that specifically addressed the use of
indocyanine green for detecting sentinel lymph nodes in breast cancer within a European population. They concluded
that fluorescence method cannot currently be considered a method fully comparable with using radioisotopes in this
setting. We consider that the absence of a learning curve, the low mean of retrieved sentinel nodes, and the possibility
that migration of indocyanine green occurred after the initial biopsy limit the strength of their conclusion.
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Dear Sir,
We read with great interest the paper published in the
journal by Oldřich Coufal and Vuk Fait entitled “Use of
indocyanine green and the HyperEye system for detect-
ing sentinel lymph nodes in breast cancer within a popu-
lation of European patients: a pilot study”. The authors
specifically report the results of indocyanine green (ICG)
for detecting sentinel lymph nodes (SLNs) in a European
population with breast cancer. The authors are to be
congratulated for this work.
In the view of their results, Coufal and Fait concluded
that fluorescence method using ICG cannot currently be
considered a method fully comparable with using radio-
isotopes (RI) in European patients. Also, their study is
well conducted and we have some remarks about this
conclusion.
Coufal and Fait have well-recognized expertise in surgi-
cal oncology. Despite the shorter learning curve than other
methods, detecting SLN using fluorescence imaging with
ICG—as all other techniques in SLN—has its own learning
curve independent of surgical expertise. It is not clearly
mentioned if the authors performed other ICG procedures
before starting the study or if they just received technical
assistance from a HyerEye technician. It is difficult to com-
pare the results of a newly implanted technique with those
of a technique performed for many years.
The mean number of retrieved sentinel nodes using
ICG in the abovementioned study is 1.3 per patient. This
value is lower than the published data using NIR in
which the mean number of nodes is generally closer to
an interval between 2 and 4 per patient [1–3] even in a
European population [4–6]. It is well known that a lower
number of retrieved nodes is responsible of a higher
false negative rates. Very interestingly, the authors dem-
onstrated that all sentinel nodes extirpated by the sole
gamma probe demonstrated ex vivo fluorescence. They
should be congratulated for doing this; they concluded
that the problem is that tissue permeability to fluores-
cence is the limitative factor and not the insufficient
transport of ICG. Another explanation of the absence of
fluorescence of sentinel nodes is that ICG passage oc-
curred after the retrieval of SLN using NIR probe. It
would be therefore not a question of permeability but of
time interval between ICG administration and SLN
biopsy.
The main merit of the study by Coufal and Fait is that
it raises an important issue that can emerge when apply-
ing new techniques in a different setting of populations
with different characteristics and particularly BMI in this
situation. However, in our opinion its statistical power
(two positive SLN/ten patients; one false negative) makes
it unable to confirm or not to confirm results from pre-
vious studies.
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